Abiogen Pharma snaps up majority stake in EffRx Pharmaceuticals
EffRx Pharmaceuticals develops and commercialise prescription drugs that target musculoskeletal and rare pathologies on European and global markets…
Pyxis Oncology to acquire biopharmaceutical firm Apexigen for $16m
25 May 23Under the terms of the transaction, Pyxis Oncology expects to issue around 4.4 million shares of its common…
CohBar, Morphogenesis announce merger to advance late-stage oncology pipeline
24 May 23Post-merger, the combined firm, which is expected to operate as TuHURA Biosciences and trade on Nasdaq Capital Market,…
Ironwood Pharmaceuticals to acquire Switzerland-based VectivBio for $1bn
23 May 23VectivBio’s lead investigational product is apraglutide, a next-generation, long-acting synthetic GLP-2 analog in phase 3, which is being…
ReNAgade Therapeutics raises $300m in Series A funding round
23 May 23ReNAgade has developed an extensive and complementary platform that integrates its exclusive delivery technologies, such as innovative lipid…
Sweden’s Sobi agrees to acquire CTI BioPharma for $1.7bn
11 May 23The transaction, which has been unanimously approved by the Board of Directors of both the companies, is expected…
Investment consortium to acquire Syneos Health for more than $7bn
10 May 23The consortium comprising Elliott Investment Management, an affiliate of Elliott Associates, along with healthcare investment firm Patient Square…
Gilead Sciences acquires California-based biotech company XinThera
10 May 23Founded in 2021, XinThera is aiming to develop small molecule drugs for the treatment of cancer and immunologic…
Baxter to sell its BioPharma business to Advent, Warburg for $4.25bn
09 May 23The transaction includes BPS’ manufacturing facilities, along with around 1,700 employees working in Bloomington, Indiana and Halle, Germany,…
Astellas Pharma to acquire US-based biotech firm Iveric Bio for $5.9bn
01 May 23Iveric Bio is a US-based biopharmaceutical company focused on novel therapies for ophthalmologic diseases and is currently developing…